The curing characteristics, morphologies, mechanical properties, and abrasion behaviors of these composites were investigated. The curing measurements indicated that the addition of lower loading of MS-III buy BGJ398 or MS-V enhanced the lubrication of EPDM compounds and delayed the curing process. The morphological structure of the composites demonstrated that the MS-III

and MS-V were uniformly dispersed in EPDM matrix and the efficient polymer-filler interfacial interactions were constructed. In comparison with EPDM/MS-II and EPDM/MS-III, EPDM/MS-V exhibited outstanding tensile strength, tear strength, elongation at break, and abrasion resistance due to the nanometer particle dimension and good dispersion of MS-V as well as the stronger interfacial

interactions between MS-V see more and the EPDM matrix. (C) 2011 Wiley Periodicals, Inc. J Appl Polym Sci 123: 3734-3740, 2012″
“Magnetic and magnetostrictive properties of magnetic-annealed polycrystalline CoFe2O4 were investigated. The magnetic hysteresis loops showed obvious uniaxiality with an induced easy direction parallel to the annealing field. Magnetic force microscopy study revealed that the domains were fixed by magnetic annealing. The uniaxial behavior was also observed in the magnetostrictive measurement, which showed a significantly enhanced magnetostriction of – 273 PPM when the external field was applied perpendicular to the annealing field direction. A physical mechanism for the effect of magnetic annealing on polycrystalline CoFe2O4 is developed, in which the induced uniaxiality is ascribed to the realignment of easy axes in polycrystals. The uniaxial behavior of magnetism and enhanced magnetostriction could be well explained by this model. (C)

2011 American Institute of Physics. [doi:10.1063/1.3624661]“
“The BEAUTIFUL (morBidity-mortality EvAlUaTion of the If inhibitor ivabradine in patients with coronary artery disease and left ventricULar systolic dysfunction) study Selleckchem PP2 assessed the morbidity and mortality benefits of the HR-lowering agent ivabradine. The placebo arm of the BEAUTIFUL trial was a large cohort of patients with stable coronary artery disease (CAD) and left ventricular systolic dysfunction. A subanalysis in the placebo group tested the hypothesis that elevated resting HR at baseline was a marker for subsequent cardiovascular death and morbidity. The primary aim of the study was to test whether lowering the HR with ivabradine reduced cardiovascular death and morbidity in patients with CAD and left ventricular systolic dysfunction. In the overall analysis, reduction in HR with ivabradine did not improve cardiac outcomes compared with placebo. The most important finding of the study was that patients with high baseline HR had an increase in serious cardiovascular events including death (34%), hospital admission secondary to congestive heart failure (53%), acute myocardial infarction (46%), or revascularization procedure (38%).